Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Brahmer, 2020, KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%, Ann. Oncol., 31, 10.1016/j.annonc.2020.08.2284 Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824 Bagley, 2017, Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Canc., 106, 1, 10.1016/j.lungcan.2017.01.013 Khunger, 2018, Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients, PloS One, 13, 10.1371/journal.pone.0197743 Shaverdian, 2017, Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol., 18, 895, 10.1016/S1470-2045(17)30380-7 Haratani, 2018, Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer, JAMA Oncol, 4, 374, 10.1001/jamaoncol.2017.2925 Tambo, 2020, Real-world efficacy of first-line pembrolizumab in patients with advanced or recurrent non-small-cell lung cancer and high PD-L1 tumor expression, Clin. Lung Canc., 21, e366, 10.1016/j.cllc.2020.02.017